Conditions: Corneal Neovascularization
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 9
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the effectiveness and safety of ranibizumab (Lucentis) in treatment of corneal neovascularization.

Detailed description:
This is an open label, single site, uncontrolled, single group assignment, safety/efficacy, Phase I study of topical administered ranibizumab in subjects with corneal neovascularization. Ten eyes of patients with corneal neovascularization will be recruited. Patients with superficial or deep corneal neovascularization that extends farther than 2 mm from the limbus will be considered.

Arms:
arm 1: 10 Patients will receive treatment (Ranibizumab)

Interventions: intervention 1: Ranibizumab
Intervention descriptions: intervention 1: 10 Patients will receive treatment (Ranibizumab)

Protocol document: